ArticleFrontiers in cellular and infection microbiology2021
Anticolonization of Carbapenem-Resistant
Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Article
- [Gut microbiota-associated metabolites with drug-induced liver injury].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Article
- Molecular Insights into Carbapenem Resistance inInternational journal of molecular sciences · 2026Review
- Microbiome-mediated colonization resistance to carbapenem-resistant Klebsiella pneumoniae in ICU patients.NPJ biofilms and microbiomes · 2025Article
- Clinical use of tigecycline may contribute to the widespread dissemination of carbapenem-resistant hypervirulentEmerging microbes & infections · 2024Article
- Impact of ExogenousAntibiotics (Basel, Switzerland) · 2024Article
- Article
- Cell-free supernatant ofFrontiers in cellular and infection microbiology · 2024Article
- Unraveling the relationship between gut microbiota and site-specific endometriosis: a Mendelian randomization analysis.Frontiers in microbiology · 2024Article
- Oral Administration ofMicroorganisms · 2023Article
- Respiratory Commensal Bacteria Increase Protection against Hypermucoviscous Carbapenem-ResistantPathogens (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.